WCE was shown to be effective in suppressing crosstalk between the AR and HER2/3 signaling in an in vivo adapted castration-resistant prostate cancer LNCaP cell model that was insensitive to androgen withdrawal and second-line antiandrogen, enzalutamide and offer evidence that the use of a clear, single plant-derived extract can increase the therapeutic efficacy of castration with expressively prolonged progression-free survival warranting further clinical studies [169]. Here, ERBB2 is linked to prostate cancer.